Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.56 |
| ▸ | CTSL | P07711 | 4/20 | 0.53 |
| ▸ | CTSB | P07858 | 3/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | CTSH | P09668 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6620586 | 0.84 | MAPT (0.52) | CTSKCTSLCTSBSYK | |
| SCHEMBL6622828 | 0.84 | MAPT (0.52) | CTSKCTSLCTSBSYK | |
| SCHEMBL6620590 | 0.84 | MAPT (0.52) | CTSKCTSLCTSBSYK | |
| SCHEMBL6621080 | 0.84 | MAPT (0.52) | CTSKCTSLCTSBSYK | |
| SCHEMBL5743140 | 0.80 | CTSL (0.50) | CTSKCTSLCTSBSYK | |
| SCHEMBL5743142 | 0.80 | CTSL (0.50) | CTSKCTSLCTSBSYK | |
| SCHEMBL2249922 | 0.80 | CTSL (0.50) | CTSKCTSLCTSBSYK | |
| SCHEMBL2249917 | 0.80 | CTSL (0.50) | CTSKCTSLCTSBSYK | |
| SCHEMBL5765656 | 0.80 | CTSL (0.50) | CTSKCTSLCTSBSYK | |
| SCHEMBL5765651 | 0.80 | CTSL (0.50) | CTSKCTSLCTSBSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745489-B2 | Compositions and methods for inhibition of phospholipase A2 mediated inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-06-29 | — | — | US | disclosed |
| US-20050148549-A1 | Compositions and methods for inhibition of phospholipase a2 mediated inflammation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148549-A1 | Compositions and methods for inhibition of phospholipase a2 mediated inflammation | PLA2G4A, PLA2G4B, PLA2G1B | CTSK 458/4885CTSL 535/4885CTSB 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.